Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study

Mauro, Fr;Tedeschi, A;Piciocchi, A;Motta, M;Iannella, E;Farina, L;Scarfo, L;Marasca, R;COSCIA, Marta;Cortelezzi, A;Laurenti, L;Melpignano, A;Zinzani, Pl;Molica, S;Re, F;Andriani, A;Vincelli, Di;Visco, C;Gozzetti, A;Orlandi, Em;Trentin, L;Tani, M;Califano, C;Tagariello, G;Ghia, P;Caputo, Md;Salaroli, A;Innocenti, I;Frustaci, A;VITALE, Candida;Petulla, M;de Fabritiis, P;Vignetti, M;Fazi, P;Foa, R.

2016-01-01